Not available
Quote | Arcturus Therapeutics Ltd. (NASDAQ:ARCT)
Last: | $21.45 |
---|---|
Change Percent: | 0.27% |
Open: | $21.87 |
Close: | $21.45 |
High: | $22.175 |
Low: | $20.85 |
Volume: | 432,847 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Arcturus Therapeutics Ltd. (NASDAQ:ARCT)
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-01 16:59:38 ET More on Arcturus Therapeutics Arcturus: A Hidden Gem In The Biotech Sector Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Ar...
Message Board Posts | Arcturus Therapeutics Ltd. (NASDAQ:ARCT)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $ARCT 30% v4,9M c20.17 f26,5M H20.74 ML14.21 gap N Hold18 | znewcar1 | investorshangout | 03/30/2023 3:18:11 AM |
whytestocks: $ARCT News Article - Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today? | whytestocks | investorshangout | 11/02/2022 3:15:49 PM |
znewcar1: ARCT 25% v1M c20.88 f26,4M H20.89 | znewcar1 | investorshangout | 05/27/2022 8:26:13 PM |
Silence is golden ARC | IOUBLOKE1 | investorshub | 12/20/2021 3:43:30 PM |
Wow big after hours green buy | IOUBLOKE1 | investorshub | 12/17/2021 10:01:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...
Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasda...